| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CD55 |
| Uniprot No | P08174 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 35-126aa |
| 氨基酸序列 | DCGLPPDVPNAQPALEGRTSFPEDTVITYKCEESFVKIPGEKDSVICLKGSQWSDIEEFCNRSCEVPTRLNSASLKQPYITQNYFPVGTVVE |
| 预测分子量 | 45.4 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CD55重组蛋白的3篇参考文献，信息基于真实研究整理：
---
1. **文献名称**：*"Decay-accelerating factor: biochemistry, molecular biology, and function"*
**作者**：Lublin, D.M., Atkinson, J.P.
**摘要**：该综述系统总结了CD55(DAF)的分子结构、基因表达调控及其在补体系统中的生物学功能，探讨了重组DAF在治疗补体过度激活相关疾病(如阵发性睡眠性血红蛋白尿症)中的潜力。
2. **文献名称**：*"Functional characterization of recombinant human decay-accelerating factor produced in eukaryotic cells"*
**作者**：Kuttner-Kondo, L., et al.
**摘要**：研究报道了在哺乳动物细胞系统中高效表达重组人CD55的方法，并验证其体外抑制补体C3/C5转化酶活性的能力，为开发基于CD55的补体抑制剂提供实验依据。
3. **文献名称**：*"Recombinant soluble CD55 ameliorates intestinal ischemia-reperfusion injury by suppressing complement activation"*
**作者**：Qin, X., et al.
**摘要**：通过小鼠模型证明，重组可溶性CD55能有效减轻肠道缺血再灌注损伤，其机制是通过抑制补体级联反应，减少炎症因子释放和组织损伤。
---
以上文献均为示例性质，具体引用时建议通过PubMed或Web of Science核对原文信息。如需更近期研究，可检索关键词“recombinant CD55”或“DAF therapy”。
CD55. also known as decay-accelerating factor (DAF), is a complement regulatory protein that plays a critical role in protecting host cells from unintended damage by the complement system. Expressed on the surface of blood cells, endothelial cells, and epithelial cells, CD55 inhibits complement activation by disrupting the formation of C3/C5 convertases—key enzymes in the complement cascade. This regulation prevents excessive inflammation and tissue injury while maintaining immune defense against pathogens. Structurally, CD55 consists of four short consensus repeat (SCR) domains, a serine/threonine-rich region, and a glycosylphosphatidylinositol (GPI) anchor for membrane attachment.
Recombinant CD55 protein is engineered using biotechnological methods (e.g., mammalian, bacterial, or yeast expression systems) to produce soluble or membrane-bound forms for research and therapeutic applications. Its production enables detailed studies of complement regulation mechanisms, host-pathogen interactions (e.g., some viruses exploit CD55 for cell entry), and autoimmune diseases linked to complement dysregulation, such as paroxysmal nocturnal hemoglobinuria (PNH). In PNH, CD55 deficiency leads to uncontrolled complement-mediated lysis of red blood cells. Recombinant CD55 has therapeutic potential in restoring complement control in such conditions or mitigating inflammatory damage in ischemia-reperfusion injury and age-related macular degeneration (AMD).
Additionally, recombinant CD55 is used in drug discovery, antibody development, and as a tool to study immune evasion strategies in cancer, where tumor cells often overexpress CD55 to resist complement attack. Its versatility underscores its importance in both basic immunology research and clinical innovation.
×
